The Healthcare Group at Frost & Sullivan is pleased to announce its Exclusive Healthcare 2006 Quarterly Analyst Briefing Presentation on the Drug Discovery Technologies market to be held on Thursday, April 20, 2006 at 12:00pm CT / 1:00pm ET. This briefing will benefit supply side participants in the infectious disease IVD market.
Molecular diagnostics offer compelling clinical utility for infectious disease diagnostic testing. The current dynamics of the market and the clinical laboratory with regard to molecular infectious disease testing will be explored in this analyst briefing.
Highlights of the briefing include: an overview of diagnostic infectious disease testing, emerging trends in the healthcare setting, analysis of drivers restraints and challenges facing the infectious disease diagnostic market, market forecasts for molecular infectious disease tests, substitute threats from immunoassay and microbiology culture infectious disease tests.
"Tremendous growth is expected in the molecular infectious disease IVD market in specific areas," says Martin Nejat, Frost & Sullivan Drug Discovery Research Analyst. "Emerging threats from avian flue, sepsis, nosocomial infections are driving growth. Understanding the pressures inherent in the US clinical laboratory is critical for success in this dynamic market."
Frost & Sullivan will hold this conference call at 12:00 pm (CT) / 1:00 pm (ET) on Thursday, April 20, 2006. To participate, please email Melina Trevino at melina.trevino[.]frost.com with the following information: Name, Company, Title, Telephone Number, and email. Upon receipt of the above information, a registration link will be emailed to you.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.